Baxalta Incorporated
Case brief
What is this about?
The Competition Commission approved the acquisition of Baxter's bioscience business by Baxalta. The Commission found no horizontal or vertical overlaps and concluded the structural separation would not impact competition in India.
What did the court decide?
The combination was approved under sub-section (1) of Section 31 of the Act.
What the court decided
Fair Competition For Greater Good
COMPETITION COMMISSION OF INDIA
(Combination Registration No. C-2015/07/297)
08.09.2015
Notice u/s 6 (2) of the Competition Act, 2002 given by
Baxalta Incorporated (“Baxalta” or the “Acquirer”)
Order under sub-section (1) of Section 31 of the Competition Act, 2002
CORAM:
Mr. Ashok Chawla Chairperson
Mr. S. L. Bunker Member Mr.Sudhir Mital Member Mr. Augustine Peter Member Mr. M.S. Sahoo Member Mr. U. C. Nahta Member Mr. G. P. Mittal Member
Legal representative: AZB & Partners
- On 30.07.2015, the Competition Commission of India (“ Commission ”) received a notice under sub-section (2) of Section 6 of the Competition Act, 2002 (“ Act ”) given by Baxalta (“ Notice ”). The Notice has been filed pursuant to the execution of Global Separation and Distribution Agreement (“ GSDA ”) between Baxter International Inc. (“ Baxter ”) and Baxalta, on 30.06.2015. As per the details
Issues for consideration
1 issue framed by the court
Whether the proposed combination of Baxalta acquisition of Baxter's bioscience business is likely to have an appreciable adverse effect on competition in India.
Parties & counsel
- applicant
Baxalta Incorporated
Coram
Ashok Chawla
S. L. Bunker
Sudhir Mital
Case details
As recorded by the court registry
All orders in this case
2 orders share this CNR
- Order 1 — this page
- Order 2
Similar cases
Judgements on the same questions, provisions and authorities, from every court